Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,418
  • Shares Outstanding, K 24,403
  • Annual Sales, $ 10,640 K
  • Annual Income, $ -51,450 K
  • 60-Month Beta 2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.83
  • Number of Estimates 4
  • High Estimate -0.81
  • Low Estimate -0.85
  • Prior Year -0.76
  • Growth Rate Est. (year over year) -9.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.99 +37.34%
on 01/03/20
7.48 -26.74%
on 01/17/20
-0.21 (-3.69%)
since 12/24/19
3-Month
3.69 +48.51%
on 11/26/19
7.48 -26.74%
on 01/17/20
+0.58 (+11.84%)
since 10/24/19
52-Week
2.69 +103.72%
on 08/14/19
9.03 -39.31%
on 03/04/19
unch (unch)
since 01/24/19

Most Recent Stories

More News
Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive...

MNLO : 5.48 (-8.67%)
FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Foamix Pharmaceuticals Ltd. (NasdaqGS: FOMX ) to...

FOMX : 4.16 (-1.89%)
MNLO : 5.48 (-8.67%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 5.48 (-8.67%)
FOMX : 4.16 (-1.89%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX) in connection...

FOMX : 4.16 (-1.89%)
MNLO : 5.48 (-8.67%)
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

-- Menlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements Foamix's existing portfolio and addresses a significant unmet medical need for a serious disease state

MNLO : 5.48 (-8.67%)
Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 5.48 (-8.67%)
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

- Pivotal results expected in March/April 2020 -

MNLO : 5.48 (-8.67%)
Menlo Therapeutics to Host Investor Day October 29, 2019

-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant-

MNLO : 5.48 (-8.67%)
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with...

MNLO : 5.48 (-8.67%)
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive...

MNLO : 5.48 (-8.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade MNLO with:

Business Summary

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic...

See More

Key Turning Points

2nd Resistance Point 6.43
1st Resistance Point 5.95
Last Price 5.48
1st Support Level 5.20
2nd Support Level 4.93

See More

52-Week High 9.03
Fibonacci 61.8% 6.61
Fibonacci 50% 5.86
Last Price 5.48
Fibonacci 38.2% 5.11
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar